$bluebird bio(BLUE.US)$With all the 13G and G/A filed recently. Im thinking that news of LOVO-CEL Commercial launch could be coming soon? That sure would increase the company’s financial position! Hehehe
Recent insider selling at bluebird bio, lack of insider buying, and low insider ownership raise caution. The company has 3 warning signs, 2 of which are concerning. bluebird bio may not be the best stock to buy.
$bluebird bio(BLUE.US)$Bluebird Bio Provides Update; Sees Prelim. Unaudited Cash And Cash Equivalents ~$275M Benzinga· 3 mins ago Significant momentum behind LYFGENIA launch with 35 Qualified Treatment Centers accepting patient referrals and payer agreements in place covering approximately 200 million U.S. lives Anticipate 85 to 105 patient starts (cell collections) across commercial portfolio in 2024 with first patient start for LYFGENIA expected in Q1 2024 Cash, cash equivalents and mar...
$bluebird bio(BLUE.US)$Bluebird Bio Has Signed A Second Outcomes-Based Agreement For LYFGENIA, Bringing The Total Number Of Covered Lives To ~200M, And Will Provide Updates On The Commercial Launch At The 42nd Annual J.P. Morgan Healthcare Conference
72812736 : 鬱悶